An online registry will be launched soon to register the rising number of hepatitis patients in India, a leading gastroenterologist said here on Friday.
The registry will be part of the newly formed Indian National Association for Study of the Liver and Current Perspective in Liver Disease.
Under the initiative, member physicians and health workers will keep a record of the number of people suffering from hepatitis and other liver diseases caused by it.
Following that the association will disseminate information to regional hospitals and healthcare facilities to tackle the disease in a proper way.
The association will also help in making medicines available to the health centres located in the remote areas of the country.
Noting that hepatitis was 28 times more dangerous than AIDS due to the absence of symptoms while it progresses in a patient, the experts said the need of registry was felt as over 75 percent of the people in India did not even know that a disease like hepatitis exists.
According to the All India Institute of Medical Sciences (AIIMS) four lakh people die due to liver diseases, a result of hepatitis, in India every year.
The states most affected by the disease are Punjab, Haryana, Odisha, Uttarakhand and Himachal Pradesh.
"75 percent of the hepatitis may it be B or C is curable at the initial stage. However, as the symptoms are not felt so the person gets to know about it only when virus causes liver cancer," said S.K. Acharya, head of gastroenterology at AIIMS.
Acharya said through the registry the hot spots of hepatitis across the country can be highlighted and healthcare in those areas improved.
Anil Arora, a gasteroenterologist at city-based Sir Ganga Ram Hospital, said: "Currently, the medicines available for hepatitis are very expensive and are not affordable for every citizen, so through this registry we will first of all look for the hotspots of hepatitis in the country and then raise awareness among them including providing the facilities so that the disease is diagnosed early."
A new drug Sofosbuvir is believed to be the perfect cure for Hepatitis C patients with in 24 weeks. However, the medicine currently costs over Rs.1 lakh for the entire therapy which is unaffordable for the economically weaker sections.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
